Registry of Patients Being Treated With Norditropin, Recombinant Human Growth Hormone

Trial Profile

Registry of Patients Being Treated With Norditropin, Recombinant Human Growth Hormone

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Somatrogon (Primary)
  • Indications Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
  • Focus Therapeutic Use
  • Acronyms ANSWER
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 20 Mar 2018 Results (n=304) assessing the long term safety and effectiveness data on adult patients with growth hormone deficiency treated with Norditropin (somatropin), presented at The 100th Annual Meeting of the Endocrine Society.
    • 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society
    • 11 Apr 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top